Introduction
early-stage ERBB2/HER2-positive, breast cancer
BREAST CANCER
During the last 2 decades, the outcome of patients with early-stage ERBB2/HER2-positive breast cancer has markedly improved owing to new treatment strategies combining polychemotherapy and multiple ERBB2/HER2-targeted drugs.Increasing evidence suggests that the activation of the host immune system mediates the response to ERBB2/HER2-targeted therapies in breast cancer.